Privacy statement


This privacy statement covers the processing of personal data that we, as Salvia BioElectronics B.V. (hereinafter: Salvia or We/we), collect as part of our services and through our website.

We take your privacy seriously and work in accordance with the General Data Protection Regulation (GDPR). We only collect personal data that is necessary to provide our services or information that you have requested. We process and secure your personal information with the utmost care. We want to be transparent about this, so below we explain how we handle your personal information.

1. Contact details

For the processing of data, Salvia is the data controller under the General Data Protection Regulation (GDPR). Salvia is located at High Tech Campus 37, 5656 AE Eindhoven, The Netherlands.  

If you have any questions about your privacy, your rights or this privacy statement, please send an e-mail to

2. What personal data we process and why

Below you will find an overview of the purposes for which we process personal data:

Newsletter registration and contact form
When you send a message to Salvia via the contact form or voluntarily subscribe to our "Salvia Insights" newsletter, we process personal information such as your name and email address. We value your privacy and will only use your email address to respond to your message or, in the case of the newsletter, to send you periodic updates about Salvia. You may unsubscribe at any time by sending an email to

When you visit our website, cookies are set. A cookie is a small text file that is stored on your computer, tablet or smartphone the first time you visit our website. The cookies we use are necessary for the technical operation of the website and your ease of use. They ensure that the website functions properly and, for example, remember your preferences. They also allow us to optimize our website. You can opt out of cookies by setting your Internet browser to not store cookies. You can also use your browser settings to delete any previously stored information. If we use cookies to track your browsing behavior, we will ask for your permission. Our Cookie Statement explains how we collect, use and safeguard your information when you visit our website: Read our Cookie Statement.

3. Sharing your personal data with third parties:

Salvia will never give or sell your personal information to third parties. We do not share your personal information with third parties unless it is necessary to provide our services or we are required to do so by law. Where necessary, we use the services of ICT suppliers. These suppliers are only eligible if they have implemented data security in accordance with the GDPR guidelines. Processors may only process personal data on our behalf and under our supervision, only for the purposes we specify and under strict confidentiality.

4. Retention periods 

Personal information is collected for the purpose of providing information in our newsletter system. We retain this information to periodically update you on topics that may be of interest to you. We take your privacy very seriously and will only use your email address to send you updates about Salvia. If you wish to unsubscribe, you may do so at any time by sending an email to

5. How we secure personal data

Salvia BioElectronics does not use automated data collection or decision-making (profiling). We make every effort to protect your privacy and process your personal data in accordance with GDPR guidelines. We therefore take organizational and technical security measures to prevent theft, misuse, loss, unauthorized access, unwanted disclosure, unauthorized modification or other unlawful use of your personal data.

If and to the extent that data is provided to third parties who process personal data on our behalf, we have agreed with them that they will also provide optimal security for this personal data. If you believe that your information is not being properly protected, or if there is any indication of misuse, please contact us immediately.

6. Your rights

You have the right to access your personal data and to request correction, restriction or deletion of your personal data. You may also object to the use of your data. If you have consented to the processing of your data, you may withdraw your consent at any time. You can send us your request to exercise these rights. We will verify your identity to ensure that your request is genuine.

If you have a complaint about the way we process your personal data, you can submit it to the Personal Data Authority.

7. Not part of this Privacy Statement

This Privacy Statement does not apply to third-party applications, products, services, websites or social media features that may be accessed through links we provide on our website for your information or convenience. If you follow these links, you will leave the Salvia BioElectronics website and information about you may be collected or shared by a third party. We have no control over these third-party websites or their privacy policies, which may differ from ours. We do not endorse or recommend third-party websites. We encourage you to review the privacy policies of each website you visit before consenting to the collection and use of your personal information.

8. Updates and Changes

Salvia may update this privacy statement and/or cookie statement. Changes will be published on our website. Please check this page periodically so that you are aware of any changes.

This Privacy Statement was last updated on December 6, 2023.

Page Title (H1)

Understanding Migraine and Cluster Headache


Migraine affects more than one billion people worldwide each year and is the leading cause of disability in people under 50. Although migraine feels different for each person, episodes typically last 4 to 72 hours and are characterized by a severe throbbing headache on one side of the head that worsens with physical activity. Accompanying symptoms include nausea, vomiting, increased sensitivity to light, sound or odors and cognitive and emotional disturbances, often requiring bed rest. Migraine mainly affects women between the ages of 20 and 50.

Chronic migraine is defined as having headaches at least 15 days a month, with a minimum of eight days meeting migraine criteria. It is important to note that not all people with chronic migraine have headache-free periods, also known as "crystal clear days". Some people endure unrelenting migraine symptoms without finding relief. It is important to understand that having migraine is not your fault; it is a genetic influence on a neurological disease.

Cluster headache

Cluster headache is a severe one-sided headache that causes excruciating pain behind the eye, often accompanied by tearing, sweating, drooping eyelids and nasal congestion. It is a severe neurological disorder that affects 1 in 1000 people. Attacks last 15 to 180 minutes and may occur one to eight times per day. Cluster headache is predominantly a male disorder, although the ratio of men to women has been decreasing and is now about 2:1. Cluster attacks are extremely disruptive to daily life, sometimes causing persistent headaches between attacks. Genetics play a role in their development and severity. Cluster headache is associated with a higher risk of suicidal thoughts and attempts, earning it the nickname "suicide headache". These attacks occur in clusters of one to two months, with remission periods varying from months to years. In chronic cases of cluster headache, there are no remissions or they last less than three months.

  • Gupta J, Gaurkar S S. Migraine: An Underestimated Neurological Condition Affecting Billions. Cureus 14(8): e28347. doi:10.7759/cureus.28347 (August 24, 2022)
  • Steiner, T.J., Stovner, L.J., Vos, T. et al. Migraine is first cause of disability in under 50s: will health politicians now take notice?. J Headache Pain 19, 17 (2018)
  • Olesen J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
  • Sutherland HG, Albury CL, Griffiths LR. Advances in genetics of migraine. Journal of Headache and Pain. 2019;20(1). doi:10.1186/s10194-019-1017-9
  • Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019;37(4):631-649. doi:10.1016/j.ncl.2019.06.001
  • Burstein R, Jakubowski M, Rauch SD. The science of migraine. J Vestib Res. 2011;21(6):305-314. doi:10.3233/VES2012-0433
  • Schroeder RA, Brandes J, Buse DC, et al. Sex and Gender Differences in Migraine - Evaluating Knowledge Gaps. J Womens Health. 2018;27(8):965-973. doi:10.1089/jwh.2018.7274
  • Rainero I, Vacca A, Govone F, Gai A, Pinessi L, Rubino E. Migraine: Genetic Variants and Clinical Phenotypes. Curr Med Chem. 2019;26(34):6207-6221
  • American Headache Society. New research on the burden of cluster headache. (March 21, 2023)
  • Rozen TD, Fishman RS. Cluster Headache in the United States of America: Demographics, Clinical Characteristics, Triggers, Suicidality, and Personal Burden. Headache. 2012;52(1):99-113. doi:10.1111/j.1526-4610.2011.02028.x
  • Jürgens TP. Comment: Sex-specific differences in cluster headache -: Not a males-only disorder. Neurology. 2017;88(11):1074. doi:10.1212/WNL.0000000000003723
  • D’Amico D, Raggi A, Grazzi L, Lambru G. Disability, Quality of Life, and Socioeconomic Burden of Cluster Headache: A Critical Review of Current Evidence and Future Perspectives. Headache. 2020;60(4):809-818. doi:10.1111/head.13784
  • Göbel CH, Karstedt S, Heinze A, Koch B, Göbel H. Phenotype of Cluster Headache : Clinical Variability, Persisting Pain Between Attacks , and Comorbidities - An Observational Cohort Study in 825 Patients. Published online 2021. doi:10.1007/ s40122-021-00267-8
  • Ji Lee M, Cho SJ, Wook Park J, et al. Increased suicidality in patients with cluster headache. Cephalalgia. 2019;39(10):1249-1256. doi:10.1177/0333102419845660

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

  • Opsomming List Item
  • Opsomming List Item
  • Opsomming List Item
  1. Opsomming List Item
  2. Opsomming List Item
  3. Opsomming List Item
Block Quote
Other articles

Some more articles you might like...


Salvia Selected for MedTech Innovator Accelerator 2024

Salvia BioElectronics is one of the companies selected for the MedTech Innovator Accelerator 2024. "We are absolutely thrilled," says Salvia CEO Hubert Martens. "With over 1300 applicants, only the top 5% made it through the rigorous selection process; this is an amazing group to be a part of. We're looking forward to connecting with like-minded entrepreneurs and are excited to have the opportunity to learn from the best in class and get expert support to further detail and pressure test our commercialization plans."

Read article

It is not “just a headache”

Migraine affects more than one billion people worldwide each year and is the leading cause of disability in people under 50. Cluster headache, which causes excruciating pain behind the eye, is a rare neurological disorder affecting 1 in 1000 people. Read more about both conditions we address with our bioelectronic solution.

Read article